Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.

ABSTRACT:

Background

Prostate cancer (PC) is the second most common cancer among men worldwide. Currently, the most common non-invasive approach for screening and risk assessment of PC is measuring the level of serum prostate-specific antigen (PSA). However, the sensitivity of PSA is 42.8 % and specificity is 41.1%. As a result, the serum PSA test leads to numerous unneeded biopsies. Therefore, a rigorous search for biomarkers for early detection of PC is ongoing. In this study, we aim to assess a panel of epigenetic markers in an intend to develop an early detection test for PC.

Results

The sensitivity and specificity of hypermethylation of MCAM was 66% and 73% respectively which is an improvement from the sensitivity and specificity of PSA. Considering a combination marker panel of

SUBMITTER: Brait M 

PROVIDER: S-EPMC5362497 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature